4.5 Interaction with other medicinal products and other forms of interaction  
 No formal assessments of pharmacokinetic interactions between Arsenic trioxide medac and other therapeutic medicinal products have been conducted.  
 Medicinal products known to cause QT/QTc interval prolongation, hypokala emia or hypomagnesaemia 
 QT/QTc prolongation is expected during treatment with arsenic trioxide, and torsade de pointes and complete heart block have been reported. Patients who are receiving, or who have received, medicinal products known to cause hypokala emia or hypomagnesaemia, such as diuretics or amphotericin  B, may be at higher risk for torsade de pointes. Caution is advised when Arsenic trioxide medac is coadministered with other medicinal products known to cause QT/QTc interval prolongation such as macrolide antibiotics, the antipsychotic thioridazine, or medicinal products known to cause hypokalaemia or hypomagnesaemia. Additional information about QT prolonging medicinal agents, is provided in section  4.4. 8  Medicinal products known to cause hepatotoxic effects 
 Hepatotoxic effects may occur during the treatment with arsenic trioxide, caution is advised when Arsenic trioxide medac is coadministered with other m edicinal products known to cause hepatotoxic effects (see section  4.4 and 4.8). 
 Other antileukaemic medicinal products  
 The influence of Arsenic trioxide medac on the efficacy of other antileukaemic medicinal products is unknown. 
 
